IRIS
DIGIACOMO, GRAZIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.043
AS - Asia 1.497
EU - Europa 1.313
SA - Sud America 269
AF - Africa 80
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.208
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.008
IT - Italia 611
SG - Singapore 506
CN - Cina 370
VN - Vietnam 265
BR - Brasile 202
IE - Irlanda 156
SE - Svezia 113
HK - Hong Kong 106
DE - Germania 105
FR - Francia 59
NL - Olanda 55
ZA - Sudafrica 52
IN - India 50
BD - Bangladesh 49
RU - Federazione Russa 37
GB - Regno Unito 30
AR - Argentina 29
BE - Belgio 29
FI - Finlandia 22
AT - Austria 20
PK - Pakistan 16
CA - Canada 15
IQ - Iraq 15
KR - Corea 15
JP - Giappone 14
UA - Ucraina 14
ID - Indonesia 13
MX - Messico 13
TR - Turchia 13
ES - Italia 12
PL - Polonia 12
CI - Costa d'Avorio 11
CO - Colombia 9
EC - Ecuador 9
PH - Filippine 9
LT - Lituania 8
CZ - Repubblica Ceca 7
SA - Arabia Saudita 7
UZ - Uzbekistan 6
VE - Venezuela 6
PY - Paraguay 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
JM - Giamaica 4
JO - Giordania 4
OM - Oman 4
TN - Tunisia 4
BO - Bolivia 3
CH - Svizzera 3
CL - Cile 3
IR - Iran 3
LU - Lussemburgo 3
MY - Malesia 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
AZ - Azerbaigian 2
EG - Egitto 2
GA - Gabon 2
HU - Ungheria 2
KE - Kenya 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
MA - Marocco 2
MD - Moldavia 2
MK - Macedonia 2
PE - Perù 2
PS - Palestinian Territory 2
QA - Qatar 2
TW - Taiwan 2
AD - Andorra 1
AL - Albania 1
AO - Angola 1
BW - Botswana 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KW - Kuwait 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TZ - Tanzania 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.208
Salva come PNG Salva come JPEG
Città #
Singapore 276
Dallas 262
Ann Arbor 234
Ashburn 234
San Jose 166
Dublin 156
Chandler 148
Parma 146
Santa Clara 104
Hong Kong 102
Ho Chi Minh City 76
Los Angeles 61
Hanoi 59
Beijing 56
Boardman 54
Johannesburg 50
Milan 50
Council Bluffs 48
Shanghai 47
Munich 46
Dearborn 42
New York 41
Hefei 40
Chicago 31
Modena 31
Bologna 28
Lauterbourg 26
Nanjing 21
Princeton 21
Reggio Emilia 19
Redmond 17
São Paulo 17
Bremen 16
Buffalo 16
Vienna 15
Moscow 14
Rome 14
Columbus 13
Da Nang 13
Frankfurt am Main 13
Helsinki 13
Brussels 12
Jakarta 12
Wayne 12
Abidjan 11
Denver 11
Seoul 11
Amsterdam 10
Florence 10
Stockholm 10
The Dalles 10
Tokyo 10
Warsaw 10
Wilmington 10
Bari 9
Izmir 9
Nuremberg 9
San Mateo 9
Shenyang 9
Turku 9
Chennai 8
Des Moines 8
Haiphong 8
Jinan 8
London 8
Seattle 8
Verona 8
Woodbridge 8
Binche 7
Houston 7
Nanchang 7
Atlanta 6
Baghdad 6
Belo Horizonte 6
Brasília 6
Dhaka 6
Dong Ket 6
Follonica 6
Fremont 6
Leuven 6
Marseille 6
Phoenix 6
Phủ Lý 6
Tianjin 6
Turin 6
Wuhan 6
Bengaluru 5
Biên Hòa 5
Campinas 5
Hebei 5
Lahore 5
Montreal 5
Tashkent 5
Toronto 5
Amman 4
Bitonto 4
Bogotá 4
Brescia 4
Casalgrande 4
Düsseldorf 4
Totale 3.268
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 247
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 218
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 201
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 197
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 192
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 170
Biological hallmarks and new therapeutic approaches for the treatment of pdac 161
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 158
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 156
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 139
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 135
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 134
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 132
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 129
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 128
State of the art and perspectives in pediatric hepatocellular carcinoma 125
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 124
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 121
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 120
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells 115
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 112
Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway 104
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 72
Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor and synergizes with Colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2 67
Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies 46
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 16
Totale 5.287
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 0 0 33
2021/2022176 22 13 24 8 3 3 28 4 11 8 8 44
2022/2023619 44 56 45 39 48 58 12 60 198 6 36 17
2023/2024390 14 23 21 14 48 56 33 25 12 32 55 57
2024/20251.050 38 40 60 70 101 110 114 69 107 92 102 147
2025/20262.384 182 213 349 218 296 116 238 77 337 179 116 63
Totale 5.287